The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pilot study of redirected autologous T cells engineered to contain anti-CD19 attached to TCRζ and 4-1BB signaling domains in patients with chemotherapy-resistant or -refractory CD19+ leukemia and lymphoma.
Stephan A. Grupp
No relevant relationships to disclose
David L. Porter
Research Funding - Novartis
Bruce Levine
Employment or Leadership Position - University of Pennsylvania
Research Funding - Novartis
Michael Kalos
Employment or Leadership Position - University of Pennsylvania
Christine Strait
No relevant relationships to disclose
Susan R. Rheingold
No relevant relationships to disclose
Richard Aplenc
No relevant relationships to disclose
Carl H. June
Honoraria - Novartis
Research Funding - Novartis